Alzheimer's drugs have been a monumental failure, and it looks as if bapineuzumab might get added to the list after failing its first phase 3 trial. With a number of new treatments in development for the disease and the patent cliff taking its toll, several pharma stocks are counting on success. Watch and find out which companies those are, what investors should be looking for in regard to this recent clinical failure, and one unique way to invest in this situation.
Considering how differently the companies involved in bapineuzumab's failure reacted to the disappointment, it's important to have large dividend-paying companies in your portfolio. Fortunately, the Dow is loaded with companies with solid dividend payouts and highly sustainable business models built for the long haul. The Motley Fool's new special free report, "The 3 Dow Stocks Dividend Investors Need," all have an X factor that makes them stand out from their illustrious peers. Download the report free for a limited time.
The article Big Pharma's Next Big Failure? originally appeared on Fool.com.
Dave Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Elan, Johnson & Johnson, and Pfizer. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.